Novartis has five business segments and is supported by our global research organization, the Novartis Institutes for BioMedical Research (NIBR). These segments are strategically aligned to bring innovative, high-quality and affordable medicines and therapies to patients around the world.
Making full use of its cross-divisional cooperation potential, Novartis continually looks for opportunities to leverage the strength of its global and diverse businesses to meet patient needs and extend its differentiated leadership position.
We continuously evolve our businesses to create a patient-centered portfolio consisting of a wide range of products and treatments to address unmet medical needs.
Pharmaceuticals develops innovative, patent-protected medicines to enhance health outcomes for patients and health-care providers. The division is at the forefront of development and commercialization in oncology, primary care and specialty medicines.
Sandoz is a global leader in the rapidly growing generic industry, offering more than 1000 different types of high-quality, affordable medicines across a broad range of therapeutic areas. It is committed to increasing global access to affordable healthcare.
Vaccines and Diagnostics
Vaccines and Diagnostics is active in the development, manufacturing and marketing of vaccines, including meningococcal, influenza and travel vaccines, as well as diagnostic products that help increase blood transfusion safety.1
Alcon provides innovative products that enhance quality of life by helping people worldwide see better. Its three businesses - Surgical, Ophthalmic Pharmaceuticals and Vision Care - offer the world's widest spectrum of eye care products.
The Over-The-Counter division focuses on self care brands for consumers.
Novartis Institute for Biomedical Research
NIBR is the global research organization of Novartis. With more than 6000 scientists and physicians around the world, NIBR is focused on discovering new drugs that can change the practice of medicine.
- In January 2014, Novartis completed the divestment of its blood transfusion diagnostics unit to Grifols for USD 1.7 billion.